Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis.
about
Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Is there a benefit of first- o ...... lung cancer? a meta-analysis.
@en
Is there a benefit of first- o ...... lung cancer? a meta-analysis.
@nl
type
label
Is there a benefit of first- o ...... lung cancer? a meta-analysis.
@en
Is there a benefit of first- o ...... lung cancer? a meta-analysis.
@nl
prefLabel
Is there a benefit of first- o ...... lung cancer? a meta-analysis.
@en
Is there a benefit of first- o ...... lung cancer? a meta-analysis.
@nl
P2093
P2860
P31
P921
P356
P1433
P1476
Is there a benefit of first- o ...... lung cancer? a meta-analysis.
@en
P2093
Hai Dong Wang
Wei Qing Lin
Xiong Wen Yang
Yu Kang Kuang
P2860
P304
81090-81098
P356
10.18632/ONCOTARGET.13191
P407
P5008
P577
2016-11-07T00:00:00Z
2016-12-06T00:00:00Z